Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Schwarz Pharma AG has revealed that a law suit has been filed by Pfizer Health AB and Pharmacia Limited in the High Court of England and Wales, claiming patent infringement relating to the incontinence drug, fesoterodine.
Subscribe to our email newsletter
Schwarz Pharma is developing fesoterodine, an anti-muscarinic agent, for the treatment of overactive bladder syndrome (OABs) and urinary urge incontinence. Last month, the company successfully completed phase III clinical trials with the agent, demonstrating statistically significant improvements in symptoms of OABs, including urinary frequency and urgency, compared to placebo.
In relation to the law suit, the Germany-based company said that it remains confident in its legal position and aims to vigorously defend its intellectual property.
Fesoterodine is the second compound from Schwarz Pharma’s innovative development pipeline to complete the phase III program within the last two years. The company’s other development projects target diseases such as Parkinson’s disease, restless legs syndrome, epilepsy, and neuropathic pain.